NTN4

NTN4 (Netrin-4) is a secreted glycoprotein that functions predominantly as a tumor suppressor through direct attenuation of Wnt signaling: it binds Wnt ligands directly, and loss of NTN4 in mice accelerates tumor onset, progression, and metastasis (PMID:35687692). Its expression is governed by distal enhancer elements that loop to the NTN4 promoter, and GWAS-identified risk variants modulate this regulation—the protective allele of rs11836367 increases GATA3 binding to enhance NTN4 expression (PMID:35687692), while the risk allele of rs61938093 reduces promoter activity, and NTN4 knockdown increases proliferation and tumor growth in breast cells (PMID:32871102). In a context-dependent reversal of this suppressive role, secreted NTN4 binds integrin β1 on endometrial cancer cells to activate FAK/SRC signaling and elevate c-MYC, sustaining cancer stem cell self-renewal (PMID:38164180). NTN4 is also under post-transcriptional control in the tumor microenvironment, where macrophage-derived TNF-α drives NF-κB/HIF-1α-dependent miR-210 expression that directly targets the NTN4 3'UTR to repress its expression and promote migration (PMID:38175202). Beyond oncology, recombinant NTN4 acts downstream of TNF-α to induce MMP-3 in tenocytes (PMID:40688916) and stimulates neurite outgrowth and inflammatory cytokine production in sensory neurons and synovial fibroblasts (PMID:40136644), though receptors for these activities are not defined in the available corpus.

1. 2020 Medium

   Established that NTN4 expression is controlled by a long-range enhancer and that reducing NTN4 is pro-tumorigenic, linking a GWAS locus to a functional cancer phenotype.

   Evidence Enhancer reporter and chromatin interaction assays plus NTN4 knockdown with in vitro and xenograft readouts in breast cells

   PMID:32871102

   Open questions at the time

   • Did not identify the downstream signaling pathway through which NTN4 loss promotes proliferation
   • Transcription factor mediating the enhancer-promoter effect not defined
2. 2022 High

   Defined the core tumor-suppressor mechanism by showing NTN4 directly binds Wnt ligands to attenuate Wnt signaling, and connected the protective risk allele to GATA3-driven enhancer activation.

   Evidence CRISPR genome editing, enhancer reporter assays, mouse knockout, and direct NTN4–Wnt binding assays

   PMID:35687692

   Open questions at the time

   • No structural detail of the NTN4–Wnt interaction
   • Which specific Wnt ligands and downstream branches are affected not fully delineated
3. 2024 Medium

   Revealed a context-dependent oncogenic activity in which secreted NTN4 binds integrin β1 to drive FAK/SRC/c-MYC signaling and maintain cancer stem cells, contrasting with its tumor-suppressive Wnt-binding role.

   Evidence EXOSC5 knockdown, recombinant NTN4 rescue, NTN4–integrin β1 binding assays, tumor sphere assays, and Western blotting in endometrial cancer cells

   PMID:38164180

   Open questions at the time

   • No structural validation of the NTN4–integrin β1 interaction
   • Reconciliation of suppressive vs. oncogenic roles across tumor types unresolved
4. 2024 Medium

   Placed NTN4 under post-transcriptional control of the tumor microenvironment by showing macrophage TNF-α induces miR-210 that directly targets the NTN4 3'UTR to promote migration.

   Evidence Co-culture, miRNA microarray, luciferase reporter with 3'UTR binding-site mutation, and functional rescue in gastric cancer cells

   PMID:38175202

   Open questions at the time

   • Downstream effectors of reduced NTN4 driving migration not mapped
   • Single-lab validation
5. 2025 Low

   Extended NTN4 function beyond cancer, positioning it downstream of TNF-α and upstream of MMP-3-mediated ECM degradation in tendon, and as a pro-inflammatory and neurotrophic factor in joint tissues.

   Evidence Recombinant NTN4 stimulation of rat tenocytes (qRT-PCR, ELISA), human iPSC-derived sensory neurons (neurite outgrowth), and OA synovial fibroblasts (cytokine ELISA)

   PMID:40136644 PMID:40688916

   Open questions at the time

   • No receptor or signaling pathway identified for the neurotrophic and inflammatory effects
   • Stimulation-only assays without genetic loss-of-function
   • Single studies, not independently confirmed

• How NTN4 switches between Wnt-binding tumor suppression and integrin-β1-mediated oncogenic signaling, and which receptors mediate its non-cancer neurotrophic and inflammatory activities, remain unresolved.
• No structural model of NTN4 with any binding partner
• Determinants of context-dependent suppressive vs. oncogenic output unknown
• Receptors for tenocyte, neuron, and fibroblast responses unidentified